Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|February 21, 2018
Metabolic disposition of WTX101 (bis-choline tetrathiomolybdate) in a rat model of Wilson diseaseThomas Plitz, Lee Boyling
Scientific Reports|April 2, 2020
Copper(II)-binding equilibria in human bloodTiina Kirsipuu, Anna Zadorožnaja, Julia Smirnova, et al.
Journal of the Neurological Sciences|March 12, 2015
ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritisRobert C Sergott, Jeffrey L Bennett, Peter Rieckmann, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 23, 2003
IL-18 binding protein protects against contact hypersensitivityThomas Plitz, Pierre Saint-Mézard, Masataka Satho, et al.
European Journal of Immunology|March 25, 2005
Extracellular lysosome-associated membrane protein-1 (LAMP-1) mediates autoimmune disease progression in the NOD model of type 1 diabetesMarcelo De Carvalho Bittencourt, Suzanne Herren, Pierre Graber, et al.
The Lancet. Neurology|March 12, 2014
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trialLudwig Kappos, Hans-Peter Hartung, Mark S Freedman, et al.
The Lancet. Gastroenterology & Hepatology|October 10, 2017
Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 studyKarl Heinz Weiss, Frederick K Askari, Anna Czlonkowska, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 22, 2002
IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's diseaseAnne Corbaz, Tessa ten Hove, Suzanne Herren, et al.
Life Science Alliance|December 3, 2021
Bis-choline tetrathiomolybdate prevents copper-induced blood-brain barrier damageSabine Borchard, Stefanie Raschke, Krzysztof M Zak, et al.
Pageof 1